Molecular Biosafety

Aguiar R. , & Peterlin B. (2008). APOBEC3 proteins and reverse transcription. Virus Research, 134(1–2), 74–85.

Argyris E. , Acheampong E. , Wang F. , Huang J. , Chen K. & Mukhtar M. (2007). The interferon-induced expression of APOBEC3G in human blood-brain barrier exerts a potent intrinsic immunity to block HIV-1 entry to central nervous system. Virology, 367(2), 440–451.

Bhatti Z. , & Berenson C. (2007). Adult systemic cat scratch disease associated with therapy for hepatitis C. BMC Infectious Diseases, 7, 8–12.

Boots M. , Best A. , Miller M. , & White A. (2009). The role of ecological feedbacks in the evolution of host defense: What does theory tell us? Philosophical Transactions of the Royal Society of London B. Biological Sciences, 364(1513), 27–36.

Carthagena L. , Bergamaschi A. , Luna J. , David A. , Uchil P. & Margottin-Goguet F. (2009). Human TRIM gene expression in response to interferons. PLoS One, 4(3), e4894.

Dance G. , Sowden M. , Cartegni L. , Cooper E. , Krainer A. , & Smith H. (2002). Two proteins essential for apolipoprotein B mRNA editing are expressed from a single gene through alternative splicing. Journal of Biological Chemistry, 277(15), 12703–12709.

Dorrschuck E. , Munk C. , & Tonjes R. (2008). APOBEC3 proteins and porcine endogenous retroviruses. Transplantation Proceedings, 40(4), 959–961.

Fan B. , Cen S. , & Jiang J. (2008). Advances in the study of molecular mechanism of APOBEC3G anti-HIV-1. Acta Pharmaceutica Sinica, 43(7), 678–682.

Goila-Gaur R. , & Strebel K. (2008). HIV-1 vif, APOBEC, and intrinsic immunity. Retrovirology, 5, 51–54.

Hersberger M. , Patarroyo-White S. , Qian X. , Arnold K. , Rohrer L. & Balestra M. (2003). Regulatable liver expression of the rabbit apolioprotein B mRNA-editing enzyme catalytic polypeptide 1 (APOBEC-1) in mice lacking endogenous APOBEC-1 leads to aberrant hyperediting. Biochemical Journal, 369(Pt. 2), 255–262.

Izumi T. , Shirakawa K. , & Takaori-Kondo A. (2008). Cytidine deaminases as a weapon against retroviruses and a new target for antiviral therapy. Mini Reviews in Medicinal Chemistry, 8(3), 231–238.

Jackson R. , Ramsay A. , Christensen C. , Beaton S. , Hall D. , & Ramshaw I. (2001). Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mouse-pox. Journal of Virology, 75(3), 1205–1210.

Johnson W. , & Sawyer S. (2009). Molecular evolution of the antiretroviral TRIM5 gene. Immunogenetics, 61(3), 163–176.

Malim M. (2009). APOBEC proteins and intrinsic resistance to HIV-1 infection. Philosophical Transactions of the Royal Society of London B. Biological Sciences, 364(1517), 675–687.

Malmgaard L. (2004). Induction and regulation of IFNs during viral infections. Journal of Interferon and Cytokine Research, 24(8), 439–454.

Mangeat B. , & Trono D. (2005). Lentiviral vectors and antiretroviral intrinsic immunity. Human Gene Therapy, 16(8), 913–920.

Narvaiza I. , Linfesty D. , Greener B. , Hakata Y. , Pintel D. & Logue E. (2009). Deaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine deaminase. PLoS Pathogens, 5(5), e1000439.

Newman E. , Holmes R. , Craig H. , Klein K. , Lingappa J. & Malim M. (2005). Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Current Biology, 15(2), 166–170.

Pharm P. , Bransteitter R. , & Goodman M. (2005). Reward versus risk: DNA cytidine deaminases triggering immunity and disease. Biochemistry, 44(8), 2703–2715.

Reszka N. , Zhou C. , Song B. , Sodroski J. , & Knipe D. (2010). Simian TRIM5alpha proteins reduce replication of herpes simplex virus. Virology, 398(2), 243–250.

Rosenberg B. , & Papavasiliou F. (2007). Beyond SHM and CSR: AID and related cytidine deaminases in the host response to viral infection. Advances in Immunology, 94, 215–244.

Schaller T. , Ylinen L. , Webb B. , Singh S. , & Towers G. (2007). Fusion of cyclophilin A to Fv1 enables cyclosporine-sensitive restriction of human and feline immunodeficiency viruses. Journal of Virology, 81(18), 10055–10063.

Sokolskaja E. , & Luban J. (2006). Cyclophilin, TRIM5, and innate immunity to HIV-1. Current Opinion in Microbiology, 9(4), 404–408.

Stopak K. , & Greene W. (2005). Protecting APOBEC3G: A potential new target for drug discovery. Current Opinion in Investigational Drugs, 6(2), 141–147.

Strebel K. , Luban J. , & Jeang K. (2009). Human cellular restriction factors that target HIV-1 replication. BMC Medicine, 16, 7–48.

Takeuchi H. , & Matano T. (2008). Host factors involved in resistance to retroviral infection. Microbiology and Immunology, 52(6), 318–325.

Towers G. (2005). Control of viral infectivity by tripartite motif proteins. Human Gene Therapy, 16(10), 1125–1132.

Towers G. (2007). The control of viral infection by tripartite motif proteins and cyclophilin A. Retrovirology, 12, 4–40.

Wood A. , Webb B. , Bartosch B. , Schaller T. , Takeuchi Y. , & Towers G. (2009). Porcine endogenous retroviruses PERV A and A/C recombinant are insensitive to a range of divergent mammalian TRIM5alpha proteins including human TRIM5alpha. Journal of General Virology, 90(Pt. 3), 702–709.

Ylinen L. , Keckesova Z. , Webb B. , Gifford R. , Smith T. , & Towers G. (2006). Isolation of an active Lv1 gene from cattle indicates that tripartite motif protein-mediated innate immunity to retroviral infection is widespread among mammals. Journal of Virology, 80(15), 7332–7338.